Introduction: In addition to the active pharmaceutical ingredient (API), excipients and the pharmaceutical dosage form can also aff ect the overall eff ect of pharmacotherapy. Knowledge about these eff ects is not important only from the aspect of drug effi cacy, but also from the aspect of pharmacovigilance. Materials and Methods: This paper presents secondary academic study results. Data on the dosage form and content of excipients were taken from SmPC documents on the offi cial website of Medicines and Medical Devices Agency of Serbia. The presence of excipients with known eff ect (EKE) and their labeling was considered in accordance with the national and European regulations regarding this area. Results: We analyzed a total of 50 medicines for topical administration that are registered in Serbia. These all contained corticosteroids as API. Thirty-fi ve (70 %) of them had one or more EKE. Creams had the highest number of diff erent EKE per drug (3.25). Five out of seven identifi ed EKE have the preservative function in formulations, which could be avoided by extemporaneous drug production. The labeling of these compounds was in accordance with the regulations in most drugs. Conclusions: The cause of an adverse drug reaction should be considered in a wider context and all the drug ingredients should be taken into account. In case of topical corticosteroids, over two third of drugs have the potential to cause adverse drug reactions that are non-API-related.
INTRODUCTION
Th e defi nite goal of establishing a pharmacovigilance system is to prevent adverse drug reactions (ADRs), and the precondition for this is their understanding [1] . Th e ADRs are not only caused by the active pharmaceutical ingredient (API), but also by the excipients. Also, an important thing that can aff ect ADRs is the dosage form of the drug. It is well-known that the same doses of the same active pharmaceutical ingredient in diff erent dosage forms can exhibit diff erent eff ects [2] [3] [4] .
Generally pharmaceutical excipients are pharmacologically inactive drug constituents. However, some of them are known to cause various eff ects [5, 6] . For that reason regulatory bodies attribute special attention to the presence and labeling of excipients that can cause ADRs. Th ese excipients are called excipients with known eff ects (EKE). 'Th e Rulebook on the content and manner of marking of the external and internal packaging of the medicinal product, additional marking, as well as the instruction content for the medicinal product' from 2011 stems from the Serbian drug law. Th e EKE list is attached to this Rulebook [7] . In the European Union, this area is under the jurisdiction of the European Medicines Agency. EU EKE list is included in the Annex to the European Commission Guidelines on 'Excipients in the labelling and package leafl et of medicinal products for human use' (SANTE-2017-11668) from 2017 [8] . Th e signifi cance of the excipients in topical drugs is indicated by the requirement to list all excipients on the external package of the drug, not only EKE.
Corticosteroids are an example of APIs in which the dosage form and the excipients have a proven impact on the occurrence of ADRs. Th erefore, it is particularly signifi can to be familiar with the eff ects of excipients in formulations with topical corticosteroids to understand the therapeutic effi cacy of these drugs. Auxiliary substances, both EKE and the ones with non-proven eff ects, are important in the management of ADRs of topical corticosteroid. Within their topical application, they can be found as an offi cinal drugs (in Serbia) for treatment of skin, eyes, ear, nose and bowel diseases. It is not uncommon for topical corticosteroids to have long-term use [9,10], which increases the chances of ADRs. Th is group of drugs is prescribed for children too [11] , and they are a vulnerable population. In addition to offi cinal drugs, topical corticosteroids are also produced as magistral and galenic drugs. Th e common practice is diluting the products present on the market and thus adjusting the dosage for use in children. Th ere should be additional caution regarding patients with combined therapy.
AIM
Th e aim of this study was to consider the infl uence of the excipients and the dosage forms of topical corticosteroids on their safety profi le.
MATERIALS AND METHODS
Th is paper presents secondary academic study results. Drugs approved by Medicines and Medical Devices Agency of Serbia were chosen for this analysis. Th e drugs whose API should have local therapeutic eff ects were observed. ATC groups which contain topical corticosteroids and have registered representatives in Serbia were detected. Drugs for the treatment of infl ammatory diseases were excluded from the study. A total of fi ve ATC groups met these conditions: D07 (Corticosteroids, Dermatological preparations), R01AD (Corticosteroids), S01BA (Corticosteroids, plain), S01CA (Corticosteroids and antiinfectives in combination), S02BA (Corticosteroids).
Th e data about the drugs was downloaded from the offi cial web-site of Medicines and Medical Devices Agency of Serbia. Summary of Product Characteristics, section two (Qualitative and Quantitative Composition) and subsection 6.1 (List of Excipients) were analyzed for determining the content of excipients [12] . Excipients with known eff ects (EKE) were separated in accordance with national and European regulations [7, 8] . 'Th e Rulebook on the content and manner of marking of the external and internal packaging of the medicinal product, additional marking, as well as the instruction content for the medicinal product' [7] and the Annex to the European Commission guideline on 'Excipients in the labelling and package leafl et of medicinal products for human use' (SANTE-2017-11668) were used [8] . Th e presence of EKE and whether they were properly marked (section two of SmPC) was recorded. It was checked whether the ADRs of EKE was listed in subsection 4.8 (Undesirable eff ect) of SmPC.
RESULTS
A total of 50 drugs were analysed in this study (cutaneous preparations n=27, eye preparations n=9, ear preparations n=2, nasal preparations n=11, rectal preparations n=1 
DISCUSSION
Th is paper gives an overview of excipients with known eff ect in the all authorized local corticosteroids on the Serbian market in one place. Th e obtained results represent a secondary source of information, which is the main limiting factor of the study. Most of identifi ed EKE can cause ADR in the form of local (skin) irritation or allergies. Bearing in mind that the most common ADR of dermal topical corticosteroids are exhibited primarily on the skin (18.9 % of all adverse reactions) [ drugs (10 %). Diff erent components of lanolin can be responsible for allergic reactions, but most frequently used is lanolin alcohol. Th e prevalence of this allergy is relatively high and varies from 1.2 % to 6.9 %. Th e allergy is expressed as allergic contact dermatitis, especially with prolonged use on damaged skin .
CONCLUSION
Th e study has shown that a signifi cant number of topical corticosteroids contain EKE. Over two thirds of analyzed drugs (70 %) have the potential to cause non-API-related adverse drug reactions in a particular group of patients. Magistral preparations may be the possible solution for this problem. Most frequently detected excipients have the preservative function and they can be completely removed from the formulations in this way.
7. The Rulebook on the content and manner of marking of the external and internal packaging of the medicinal product, additional marking, as well the range of 0.8 to 3.5 % . Cetostearyl alcohol including Cetyl alcohol were detected in nine drugs (18 %) . Th ese excipients very rarely lead to irritant and allergic reactions, but there are case reports in the literature showing evidence of their harmful eff ects. Hence, care should be taken when using the preparations containing them .
Chlorocresol (detected in three drugs, 6 %) can cause contact dermatitis and contact urticaria. Th e case of life-threatening immediate hypersensitivity with anaphylaxis to chlorocresol was also documented. Th is fact makes chlorocresol an excipient with the potential for the most severe side eff ects [18] .
Th e presence of parabens was observed in 6 drugs (12 %). Parahydroxybenzoates (Parabens) have attracted a lot of attention from the general and professional public recently, due to certain claims that they have a hormonal eff ect on estrogen receptors, and consequently a carcinogenic eff ect. Th ere is still no solid evidence for these claims. Studies have shown that the toxicological potential increases with the increase of the side chain length and with benzoic ring presence [19, 20] . As methyl and propyl derivatives have been detected in this study, side eff ects are expected to be exclusively local irritation.
Fift een drugs (30 %) contained benzalkonium chloride. It is a preservative that can act as an irritant or allergen. Skin sensitization is low and appears to occur in 0.02 % to 0.7 %. Hypersensitivity reactions type 1 and type 4 may occur with ophthalmic, cutaneous, ear and inhalation applications . A high proportion (83.33 %, 5/6) of preparations with benzalkonium chloride was observed in eye drops (suspension and solution). Th is excipient can be incorporated into contact lenses, therefore a caution is necessary for the people who wear them [7, 8] . Benzalkonium chloride was also present in all ear preparations. Although these drugs are intended for topical use, due to anatomical closeness to the lungs, caution is necessary. It is known that inhalation of benzalkonium chloride can lead to serious side eff ects such as bronchospasm, especially in asthma patients [7, 8] .
Benzyl alcohol is generally safe excipient. However, studies have shown irritation potential on the skin [24] . It was found in just one drug (2 %).
Lanolin was present in fi ve analysed 
